Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis.
Nicole SanderDora StölzlMelina FonfaraJan HartmannInken HarderIna SuhrkampIvone JakašaEllen van den BogaardIvonne van Vlijmen-WillemsSilke SzymczakElke RodriguezSascha GerdesStephan WeidingerPublished in: The British journal of dermatology (2024)
Tralokinumab treatment improved skin physiology, epidermal pathology and dysbiosis, further highlighting the pleiotropic role of IL-13 in AD pathogenesis.